Investigation of inter-fraction target motion variations in the context of pencil beam scanned proton therapy in non-small cell lung cancer patients.
free breathing
inter-fractional motion monitoring
lung cancer
moving targets
pencil beam scanning proton therapy
Journal
Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746
Informations de publication
Date de publication:
Sep 2020
Sep 2020
Historique:
received:
09
03
2020
revised:
01
05
2020
accepted:
14
06
2020
pubmed:
24
6
2020
medline:
15
5
2021
entrez:
24
6
2020
Statut:
ppublish
Résumé
For locally advanced-stage non-small cell lung cancer (NSCLC), inter-fraction target motion variations during the whole time span of a fractionated treatment course are assessed in a large and representative patient cohort. The primary objective is to develop a suitable motion monitoring strategy for pencil beam scanning proton therapy (PBS-PT) treatments of NSCLC patients during free breathing. Weekly 4D computed tomography (4DCT; 41 patients) and daily 4D cone beam computed tomography (4DCBCT; 10 of 41 patients) scans were analyzed for a fully fractionated treatment course. Gross tumor volumes (GTVs) were contoured and the 3D displacement vectors of the centroid positions were compared for all scans. Furthermore, motion amplitude variations in different lung segments were statistically analyzed. The dosimetric impact of target motion variations and target motion assessment was investigated in exemplary patient cases. The median observed centroid motion was 3.4 mm (range: 0.2-12.4 mm) with an average variation of 2.2 mm (range: 0.1-8.8 mm). Ten of 32 patients (31.3%) with an initial motion <5 mm increased beyond a 5-mm motion amplitude during the treatment course. Motion observed in the 4DCBCT scans deviated on average 1.5 mm (range: 0.0-6.0 mm) from the motion observed in the 4DCTs. Larger motion variations for one example patient compromised treatment plan robustness while no dosimetric influence was seen due to motion assessment biases in another example case. Target motion variations were investigated during the course of radiotherapy for NSCLC patients. Patients with initial GTV motion amplitudes of < 2 mm can be assumed to be stable in motion during the treatment course. For treatments of NSCLC patients who exhibit motion amplitudes of > 2 mm, 4DCBCT should be considered for motion monitoring due to substantial motion variations observed.
Identifiants
pubmed: 32573792
doi: 10.1002/mp.14345
pmc: PMC7586844
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3835-3844Subventions
Organisme : University Medical Center Groningen
ID : NCT03024138
Informations de copyright
©2020 The Authors. Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine.
Références
J Digit Imaging. 2013 Dec;26(6):1045-57
pubmed: 23884657
Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1121-1128
pubmed: 28964587
Med Phys. 2015 May;42(5):2462-9
pubmed: 25979039
Med Phys. 2011 Mar;38(3):1672-84
pubmed: 21520880
Cureus. 2018 Aug 23;10(8):e3192
pubmed: 30402360
Med Phys. 2010 Sep;37(9):4874-9
pubmed: 20964205
Radiother Oncol. 2018 Feb;126(2):325-332
pubmed: 29208512
Phys Med Biol. 2008 May 7;53(9):2253-65
pubmed: 18401063
Acta Oncol. 2017 Apr;56(4):531-540
pubmed: 28358666
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):523-533
pubmed: 26725727
Phys Med Biol. 2009 Nov 7;54(21):6549-63
pubmed: 19826204
Med Phys. 2014 Apr;41(4):041912
pubmed: 24694143
Int J Radiat Oncol Biol Phys. 2012 Aug 1;83(5):1566-72
pubmed: 22391105
Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):822-34
pubmed: 12095547
Med Phys. 2015 Jan;42(1):40-53
pubmed: 25563246
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1568-75
pubmed: 21075559
J Appl Clin Med Phys. 2018 Nov;19(6):140-148
pubmed: 30328674
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1036-46
pubmed: 17379442
Cancers (Basel). 2015 Jul 02;7(3):1178-90
pubmed: 26147335
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1605-12
pubmed: 19931739
Int J Radiat Oncol Biol Phys. 2013 Jun 1;86(2):372-9
pubmed: 23462422
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):549-559
pubmed: 27084664
Radiat Oncol. 2013 Jun 15;8:144
pubmed: 23767810
Med Phys. 2017 Feb;44(2):762-771
pubmed: 27991677
Int J Radiat Oncol Biol Phys. 2014 Nov 15;90(4):809-18
pubmed: 25260491
Acta Oncol. 2018 Feb;57(2):203-210
pubmed: 28760089
Radiother Oncol. 2003 Jan;66(1):75-85
pubmed: 12559524
Med Phys. 2017 Feb;44(2):703-712
pubmed: 28133755
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):172-180
pubmed: 26700711
Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):478-92
pubmed: 26867877
Med Phys. 2019 Mar;46(3):1140-1149
pubmed: 30609061
Med Phys. 2018 Jul 16;:
pubmed: 30014478
Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):918-27
pubmed: 20950961
Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):916-23
pubmed: 24867537
Phys Med Biol. 2011 Oct 21;56(20):6563-81
pubmed: 21937770
Radiother Oncol. 2019 Jul;136:185-189
pubmed: 31015123
Trials. 2016 Nov 15;17(1):543
pubmed: 27846903
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1665-73
pubmed: 21498009
Cancers (Basel). 2019 Jan 01;11(1):
pubmed: 30609652